

Migraine is a prevalent and disabling neurological condition that imposes a substantial burden on individuals and health systems, underscoring the need for effective preventive strategies. In their Review in The Lancet Neurology,1 Daniele Martinelli and colleagues highlight the latest treatment frameworks and research in preventing migraine. Their Review arrives at a pivotal moment in migraine management, as a growing body of evidence now supports the use of migraine-specific treatments, such as calcitonin gene-related peptide (CGRP) inhibitors, over traditional generic preventive medications including anticonvulsants, antihypertensives, and antidepressants.
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet